Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

By A. Coles, C. Twyman, Douglas L. Arnold, Jeffrey A. Cohen, Christian Confavreux, E. Fox, H. Hartung, E. Havrdová, K. Selmaj, H. Weiner and 8 more. The Lancet, 2012

1,153 citations recorded by the source corpus.